Abstracts Archive - Page 1919 of 2607 - ACR Meeting Abstracts

Abstract Number: 717 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus and the Evaluation of Poor Sleep: The Sleeps Pilot Study
Alicia Hinze¹, Philip Chu¹, Dany Thekkemuriyil¹, Yo-El Ju², Deepali Sen³, Seth Eisen¹ and Alfred Kim¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Neurology, Washington University School of Medicine, Saint Louis, MO, ³Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Sleep disturbances occur in many autoimmune diseases and are ranked highly as an unmet need in patients with SLE. We hypothesized that poor sleep…
Abstract Number: 718 • 2015 ACR/ARHP Annual Meeting
Urinary MBL : A Promising Biomarker for Predicting Flare in Lupus Nephritis
Sarit sekhar Pattanaik¹, Madhukara HM¹, Aditya kumar Panda², Rashmi ranjan Sahoo¹, Rina Tripathy³ and Bidyut kumar Das¹, ¹Medicine, SCB Medical College, Cuttack, India, ²Centre for Life science, Central University of Jharkand, Ranchi, India, ³Biochemistry, SCB Medical College, Cuttack, India
Background/Purpose: Nephritis is the most common cause of mortality and morbidity in SLE, develops in 40 to 70% of cases in 5-10 years with 60%…
Abstract Number: 719 • 2015 ACR/ARHP Annual Meeting
Cell of Origin of Diffuse Large B-Cell Lymphoma (DLBCL) in Patients with Systemic Lupus Erythematosus (SLE)
Basile Tessier Cloutier¹, Pedro Farinha², Sasha Bernatsky³, Eva Baecklund⁴, Ann E. Clarke⁵, Rosalind Ramsey-Goldman⁶, Randy Gascoyne⁷ and SLICC Investigators, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Pathology, BC Cancer Agency, Vancouver, BC, Canada, ³Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁴Rheumatology, Department of Medical Sciences, University Hospital, Uppsala, Sweden, ⁵Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ⁶Fsm # M300, SLICC, Chicago, IL, ⁷Pathology, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Background/Purpose: SLE has been consistently associated with an increased incidence of malignant lymphoma, especially the DLBCL subtype. Since the last WHO classification of 2008 DLBCL…
Abstract Number: 720 • 2015 ACR/ARHP Annual Meeting
Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary Î±1-Microglobulin and Albuminâ�„Creatinine Ratio
Luca Petricca¹, Elisa Gremese¹, Laura Messuti¹, Franca Forni², Clara Di Mario¹, Marcin Nowik¹, Maria Rita Gigante¹, Gerardo Marino³ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Laboratory Medicine, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Lupus nephritis (LN) may severely affect SLE prognosis and an effective treatment of LN requires correct diagnosis, timely intervention and early treatment of any…
Abstract Number: 721 • 2015 ACR/ARHP Annual Meeting
Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus
Richard Furie¹, M Khamashta², L Wang³, J Drappa³, W Greth³ and G Illei³, ¹Division of Rheumatology, North Shore - LIJ Health System, New York, NY, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ³MedImmune, Gaithersburg, MD
Background/Purpose: Most randomized controlled trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors to ensure a balanced allocation of subgroups that might respond differently…
Abstract Number: 722 • 2015 ACR/ARHP Annual Meeting
Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
Michelle Petri¹, Wei Fu², Adnan Kiani¹, Lauren DeVine¹, Conover Talbot Jr.¹ and Robert Cole¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We have previously validated several urine proteomic biomarkers for Lupus Nephritis (osteoprotegerin, MCP-1, VCAM-1 and urine TWEAK). In this discovery effort we looked for…
Abstract Number: 723 • 2015 ACR/ARHP Annual Meeting
Oral Ulcers in Systemic Lupus Erythematosus: Characterization and Clarification of an Important Clinical Manifestation
Robert Durcan¹, Wei Fu² and Michelle Petri³, ¹Beaumont Hospital, Dublin, Ireland, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Oral ulcers (OU) are a common manifestation of systemic lupus erythematosus (SLE). They are included in both classification criteria and disease activity indices. Despite…
Abstract Number: 724 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su² and Murray Urowitz^2,3, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, its efficacy in extra-renal manifestations of…
Abstract Number: 726 • 2015 ACR/ARHP Annual Meeting
Associates of Pleurisy of Pericarditis in Systemic Lupus Erythematosus (SLE)
Seungwon Ryu¹ and Michelle Petri², ¹Konkuk University School of Medicine, Seoul, South Korea, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serositis is one of the classification criteria for systemic lupus erythematosus and a common type of extra renal flare. Comparison of associates of pleurisy…
Abstract Number: 727 • 2015 ACR/ARHP Annual Meeting
Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids
Richard Furie¹, Maya Das², Daner Li², Shanique Smythe², Ericka Mathura² and Patrice Becker², ¹Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ²Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Melanocortins such as corticotropin and alpha-MSH may modulate steroid-independent immune responses relevant to SLE pathophysiology. We previously reported that repository corticotropin injection (RCI), an…
Abstract Number: 728 • 2015 ACR/ARHP Annual Meeting
Autoimmune Hemolytic Anemia and Thrombocytopenia in a Single Centre Cohort of Patients with Systemic Lupus Erythematosus from Turkey : Clinical Associations and Effect on Disease Damage and Survival
Bahar Artim-Esen¹, Sevil Kamali¹, Ahmet Gul¹, Lale Ocal² and Murat Inanc¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Hematologic involvement is common in patients with SLE. Thrombocytopenia and autoimmune hemolytic anemia (AIHA), prevalences of which have been reported as 10-40 % and…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 730 • 2015 ACR/ARHP Annual Meeting
Early Symptoms of Systemic Lupus Erythematosus As Reported By Members of the German Lupus Erythematosus Patient Association
Nicolai Leuchten¹, Barbara Milke¹, Borgi Winker-Rohlfing², David I. Daikh³, Thomas Dorner⁴, Sindhu R. Johnson⁵, Martin Aringer¹ and on behalf of the SLE Classification Criteria Steering Committee, ¹Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ²Lupus Erythematodes Selbsthilfegemeinschaft e.V., Wuppertal, Germany, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada
Background/Purpose: EULAR and ACR have jointly funded a project to develop systemic lupus erythematosus (SLE) classification criteria, aiming at earlier and more accurate classification of…
Abstract Number: 731 • 2015 ACR/ARHP Annual Meeting
Damage and Mortality in SLE: Cluster Analysis of Patients from SLE Registry from the Spanish Society for Rheumatology (RELESSER)
JM Pego-Reigosa^1,2, Ana Lois-Iglesias^3,4, Francisco Javier Lopez Longo⁵, María Galindo⁶, J Calvo-Alen⁷, Jacobo de Uña⁸, Vanessa Balboa⁹, Alejandro Olivé¹⁰, Coral Mouriño-Rodríguez¹, Maria Teresa Oton Sanchez¹¹, Jesus Ibañez¹², Maria Loreto Horcada¹³, Ana Sánchez Atrio¹⁴, Carlos Alberto Montilla Morales¹⁵, Rafael-Benito Melero González¹, Ricardo Blanco¹⁶, Elvira Diez Alvarez¹⁷, Monica Fernandez Castro¹⁸, Esther Ruiz Lucea¹⁹, José Hernández Beiraín²⁰, Marian Gantes²¹, Blanca Hernández-Cruz²², Angela Pecondon-Español²³, Nuria Lozano-Rivas²⁴, Gema Bonilla²⁵, Vicente Torrente-Segarra²⁶, Iñigo Rúa-Figueroa²⁷ and RELESSER EASSER Group, ¹Rheumatology, EOXI Vigo, Vigo, Spain, ²Rheumatology, Instituto de Investigación Biomédica de Vigo(IBIV), Vigo, Spain, ³Rheumatology, Hospital Ntra Señora de La Esperanza, Santiago de Compostela, Spain, ⁴Rheumatology, University A Coruña, A Coruña, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁷Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ⁸Statistics and OR, Vigo University, Vigo, Spain, ⁹Statistics and OR, Viho University, Vigo, Spain, ¹⁰Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ¹¹Rheumatology, Hospital of Torrejón, Madrid, Spain, ¹²Rheumatology, Hospital Povisa, Vigo, Spain, ¹³Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁴University Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcalá de Henares, Madrid, Spain, ¹⁵Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁶Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ¹⁷Rheumatology, Hospital de León, León, Spain, ¹⁸Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ¹⁹Rheumatology, Hospital de Basurto, Bilbao, Spain, ²⁰Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ²¹Rheumatology, Hospital Universitario de Canarias, La Laguna; Tenerife, Spain, ²²Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ²³Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²⁴Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain, ²⁵Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²⁶Hospital General Hospitalet-Sant Joan Despí Moisès Broggi, Hospitalet Llobregat, Barcelona, Spain, ²⁷Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain
Background/Purpose: Damage in SLE is associated with mortality. Not every damage manifestation is associated in the same way. Some studies were made assessing this relation…
Abstract Number: 732 • 2015 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Martina Frodlund², Daniel Ramsköld¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden
Background/Purpose: Belimumab is the first biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated through 2 phase III…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].